Back to results
US 2024/0182856 A1Published application
Engineered immune cell therapies
AssigneeFactor Bioscience Inc.
InventorsMatthew ANGEL, Christopher ROHDE, Mitchell KOPACZ, Jasmine HARRIS, James PAN
Life of this patent
Estimating the term…
Abstract
The present disclosure relates in part to engineered immune cells that are, inter alia, silenced from a host immune response.
Claims21
1-117. (canceled)
A method of making an engineered immune cell, the method comprising:
- (a) providing a gene-edited induced pluripotent stem (iPS) cell, wherein the gene-edited iPS cell is generated by:
- (1) contacting a somatic cell with a ribonucleic acid (RNA) encoding one or more reprogramming factors, which results in reprogramming of the somatic cell into an iPS cell, and
- (2) causing a disruption of a beta-2-microglobulin (B2M) gene in the iPS cell by using a synthetic RNA encoding one or more gene-editing proteins;
- and
- (b) differentiating the gene-edited iPS cell into an immune cell, wherein the immune cell is a lymphoid cell or myeloid cell.
2 more elements
A composition comprising an isolated immune cell comprising a genetically engineered disruption in a beta-2-microglobulin (B2M) gene, wherein the immune cell is selected from a lymphoid cell or myeloid cell.
Dependencies are inferred from the claim text.